Curis | CRIS - Des Atouts





Des Atouts Changement Date
Alaunos Therapeutics USD 1.88M 1.08M 2026-03
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
CSL USD 37.9B 1.5B 2025-12
Curis USD 19.97M 9.27M 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Incyte USD 7.34B 381.14M 2026-03
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.45T 44.34B 2026-03
TG Therapeutics USD 1.53B 465.58M 2026-03
Verastem USD 246.44M 69.59M 2025-12
Xoma USD 263.15M 39.7M 2025-09